Helix BioPharma Corp. · TSX:HBP
Helix BioPharma — Investor Presentation (May 2023)
23 slides from Helix BioPharma's investor presentation, May 2023
Slide 1: New Directions in Cancer Therapy
New Directions in Cancer Therapy Media Presentation May 2023
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation document contains certain forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable securities laws. Forward-looking statements are statements and information that are not historical facts but
Slide 3: Executive Summary
Helix Corporate Presentation - Strictly Confidential • Helix BioPharma is developing a novel first-in-class anti-cancer therapy stemming from its proprietary technology platform • Our lead Tumor Defence Breaker™ L-DOS47 is a unique tumor microenvironment modifying drug. It breaks the tumor defence a
Slide 4: Corporate Brief
CORPORATE BRIEF § Est. 1996, clinical-stage, biopharmaceutical company § Listed/trades on the Toronto Stock Exchange (TSX): Helix BioPharma Corp. (“Helix”) / Ticker symbol – HBP § Shares outstanding: around 200 M § Share price: CAD 0.20 (05/04/2023) § Market Capitalization: CAD 40 M § Backed by high
Slide 5: Management Team
MANAGEMENT TEAM Jacek Antas, CEO Gary Renshaw, MD, CMO § Supervisory Board Chairman § Former CMO Zhejiang DTRM Biopharma § Over 25 years of experience in financial § Former oncology Director at Eisai services/Board member for various companies Hatem Kawar, CFO § Experienced CFO with proven track rec
Slide 6: Board of Directors
BOARD OF DIRECTORS Jacek Antas Jerzy Leszczynski CEO, Chair Board of Directors Board Member Christopher Maciejewski Malgorzata Laube Board Member Board Member Helix Corporate Presentation - Strictly Confidential 6
Slide 7: Oncology Remains a Significant Unmet Medical Need
ONCOLOGY REMAINS A SIGNIFICANT UNMET MEDICAL NEED Lung Cancer in US Several tumor types impacting large populations have persistently high unmet need Colorectal Cancer in US Head and Neck Cancer in US 7 From NCI SEER Program – Accessed 1/30/2023
Slide 8: Estimated IO Market by 2030
ESTIMATED IO MARKET BY 2030 Growing aging populations, increasing obesity and changes in lifestyle including smoking and drinking has led to a significant increase in patients suffering from various kinds of cancers. Increasing clinical and economic burden is putting a significant stress on our heal
Slide 9: The Hallmarks of Cancer
THE HALLMARKS OF CANCER • The characteristics of cancer can be organized into multiple hallmarks or traits • These hallmarks provide a framework to study cancer and to develop drugs • Targeted drugs are developed against specific traits, but cancers often acquire resistance and escape • Missing are
Slide 10: Effect of Acidosis on Tumor Progression
EFFECT OF ACIDOSIS ON TUMOR PROGRESSION • Hypoxia, poor vasculature and increased flux of carbons through fermentative glycolysis leads to extracellular acidosis in solid tumors (Pasteur effect). • Cancer cells can maintain the glycolytic phenotype even in the presence of oxygen (Warburg effect) cau
Slide 11: L-DOS47: A Platform Technology Targeting Tumor Microenvironment
L-DOS47: A PLATFORM TECHNOLOGY TARGETING TUMOR MICROENVIRONMENT 1. Tumor acidity is an escape mechanism that cancer cells utilize to evade the anti-tumor immune response. 2. Tumor acidity has been shown to correlate with resistance to anti-cancer treatment and poor prognosis for cancer patients. 3.
Slide 12: L-DOS47: Anti-CEACAM6-Urease Bioconjugate
L-DOS47: ANTI-CEACAM6 -UREASE BIOCONJUGATE Conjugation of urease to a tumor-specific antibody allows targeted urease delivery by iv injection 12
Slide 13: Clinical Studies
Clinical Studies €2 HELIXBIOPHARMA
Slide 14: Tumor Defence Breaker Technology Platform
TUMOR DEFENCE BREAKER TECHNOLOGY PLATFORM CLINICAL TRIALS L-DOS47 monotherapy NSCLC (clinical trial # NCT02340208) PRECLINICAL PHASE 1 PHASE 2 L-DOS47 combo PEM/CARBO NSCLC (clinical trial # NCT02309892) PRECLINICAL PHASE 1 PHASE 2 L-DOS47 combo DOXO Pancreas (clinical trial # NCT04203641) PRECLINIC
Slide 15: A Robust Clinical Strategy to Establish Safety and Efficacy of L-DOS47
A ROBUST CLINICAL STRATEGY TO ESTABLISH SAFETY AND EFFICACY OF L-DOS47 IN CANCER PATIENTS Objective Studies Status Outcomes L-DOS47 is safe and tolerated LDOS002 Phase I/II Phase I and stage 1 of phase II Safety and tolerability as a at all doses studied Monotherapy in advanced non- complete monothe
Slide 16: L-DOS47 Platform: Portfolio-in-a-Product Strategy
L-DOS47 PLATFORM: PORTFOLIO-IN-A-PRODUCT STRATEGY NSCLC L-DOS47 Platform Example companies Combination with Chemotherapy Combination with Colorectal Cancer (CRC) Chemotherapy üNSCLC – proof of concept with clinical data Head and Neck Cancer ØCRC L-DOS47 (H&N) ü CEACAM6 Expression ØH&N NSCLC Combinat
Slide 17: Intellectual Property
Intellectual Property €2 HELIXBIOPHARMA
Slide 18: Strong Barrier to Entry with IP
STRONG BARRIER TO ENTRY WITH IP RESTORING FUNCTION METHOD AND COMPOSITION FOR ANTIBODY-UREASE USE OF ANTIBODY- USE OF UREASE FOR INHIBITING TUMOR ACIDIFIED T CELLS INHIBITING CANCER CELL CONJUGATES FOR UREASE CONJUGATES CANCER CELL GROWTH GROWTH USING UREASE AND THERAPEUTIC PURPOSES FOR DIAGNOSTIC A
Slide 19: Business Development
Business Development €2 HELIXBIOPHARMA
Slide 20: Example Target Companies That Could Have Interest in L-DOS47
EXAMPLE OF TARGETS COMPANIES THAT COULD HAVE INTEREST IN L-DOS47 • Ongoing outreach to these and several other companies • Interest to use LDOS47 in combination with their assets • Could be of interest beyond current IO therapies to their growing portfolio • In combination with newer modalities like
Slide 21: Example Comps for Helix BioPharma
EXAMPLE COMPS FOR HELIX BIOPHARMA Licensor and licensee Total deal value Description ($ million), date Cullinan Oncology and $588 Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4- Harbour BioMed ($25M upfront; $148M development 1BB Bispecific Immune Activator from Harbour
Slide 22: Summary
SUMMARY 1. Current standards of care, including checkpoint inhibitors, are limited by the efficacy in addressing cancers 2. Helix is developing novel anti-cancer therapies stemming from its proprietary technology platforms that could help address these efficacy challenges turning it into a significa
Slide 23: Contact PR / IR
Helix Corporate Presentation - Strictly Confidential Contact PR / IR: Torsten Biallas b-communication GmbH Tengstrasse 27, D - 80798 München Mobile +49 172 4229605 Mobile +41 79 4753386 t.biallas@b-communication.de 23